Institution statistics

DEUTSCHES KREBSFORSCHUNGSZENTRUM - Germany

Ranking results:

Past rankings:

2018
Criterium:	Position:
Overall Score:	> 1000
Total Project Funding per Partner:	> 1000
Total Number of Projects:	> 1000
Networking Rank (Reputation):	> 1000
2017
Criterium:	Position:
Overall Score:	300-400
Total Project Funding per Partner:	100-200
Total Number of Projects:	300-400
Networking Rank (Reputation):	600-700
2016
Criterium:	Position:
Overall Score:	600-700
Total Project Funding per Partner:	200-300
Total Number of Projects:	500-600
Networking Rank (Reputation):	> 1000
2015
Criterium:	Position:
Overall Score:	200-300
Total Project Funding per Partner:	200-300
Total Number of Projects:	400-500
Networking Rank (Reputation):	> 1000
Partner Constancy:	300-400
Project Leadership Index:	82
2013
Criterium:	Position:
Overall Score:	300-400
Total Project Funding:	300-400
Total Project Funding per Partner:	200-300
Total Number of Projects:	64
Partner Constancy:	58
Project Leadership Index:	47
Diversity Index:	47
2012
Criterium:	Position:
Overall Score:	500-600
Total Project Funding:	200-300
Total Project Funding per Partner:	100-200
Total Number of Projects:	61
Networking Rank (Reputation):	300-400
Networking Rank (Reputation):	300-400
Partner Constancy:	46
Project Leadership Index:	75
Diversity Index:	37
2011
Criterium:	Position:
Overall Score:	600-700
Total Project Funding:	400-500
Total Project Funding per Partner:	400-500
Total Number of Projects:	300-400
Networking Rank (Reputation):	400-500
Partner Constancy:	700-800
Project Leadership Index:	200-300
Diversity Index:	> 1000
2010
Criterium:	Position:
Overall Score:	> 1000
Total Project Funding:	400-500
Total Project Funding per Partner:	100-200
Total Number of Projects:	500-600
Networking Rank (Reputation):	> 1000
Partner Constancy:	500-600
Project Leadership Index:	600-700
Diversity Index:	> 1000
2009
Criterium:	Position:
Overall Score:	400-500
Total Project Funding:	200-300
Total Project Funding per Partner:	100-200
Total Number of Projects:	200-300
Networking Rank (Reputation):	200-300
Partner Constancy:	600-700
Project Leadership Index:	600-700
Diversity Index:	300-400
2008
Criterium:	Position:
Overall Score:	300-400
Total Project Funding:	100-200
Total Project Funding per Partner:	100-200
Total Number of Projects:	200-300
Networking Rank (Reputation):	200-300
Partner Constancy:	200-300
Project Leadership Index:	300-400
Diversity Index:	> 1000
2007
Criterium:	Position:
Overall Score:	900-1000
Total Project Funding:	300-400
Total Project Funding per Partner:	100-200
Total Number of Projects:	200-300
Networking Rank (Reputation):	400-500
Partner Constancy:	500-600
Project Leadership Index:	600-700
Diversity Index:	> 1000

Ranking timeline:

European project participation (2000-01-01 - 2019-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 123
As coordinator: 5
As participant: 101
Sole participant: 17
Coordinator / Participant Ratio: 0.05^*

^*Ratio includes only projects with > 2 partners

Summary:

	Total project funding [€]:			Projects [No]:
Year:	coordinator^*	participant^*	per partner	as coordinator	as participant
2018	149.500	5.949.964	1.019.600	1	1
2017	0	6.906.050	6.566.250		4
2016	1.738.955	7.968.310	4.178.127	2	2
2015	2.168.794	16.047.333	6.396.631	2	5
2014	261.969	0	261.969	2
2013	6.195.747	35.879.301	4.334.619	3	7
2012	336.754	46.735.876	9.167.323	2	10
2011	8.098.428	25.638.979	3.387.602	3	5
2010	0	44.806.245	5.263.164		6
2009	100.000	42.684.009	5.275.487	1	8
2008	0	51.432.041	3.104.085		8
2007	0	5.914.351	455.959		2
2006	0	88.414.466	4.416.754		12
2005	6.644.656	70.077.480	7.339.590	4	13
2004	2.574.811	97.165.051	8.075.005	2	14
2003	0	2.200.303	275.038		2
2001	0	328.901	32.890		1
2000	0	2.625.000	238.636		1

^*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:	Projects [No]:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	23
KAROLINSKA INSTITUTE	22
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE	17
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	14
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD	13
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE	12
UNIVERSITY COLLEGE LONDON	11
EUROPEAN MOLECULAR BIOLOGY LABORATORY	10
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER	10
LUNDS UNIVERSITET	10
MEDICAL RESEARCH COUNCIL	10
CHARITE UNIVERSITAETSMEDIZIN BERLIN	8
UNIVERSITAETSKLINIKUM HEIDELBERG	8
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI	7
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV	7
UNIVERSITY OF COPENHAGEN	7
DANISH CANCER SOCIETY	6
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR	6
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III	6
INSTITUT PASTEUR	6
LEIDEN UNIVERSITY MEDICAL CENTER	6
THE UNIVERSITY OF MANCHESTER	6
UNIVERSITY OF BIRMINGHAM	6
UNIVERSITY OF HELSINKI	6
VTT TECHNICAL RESEARCH CENTRE OF FINLAND	6
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH	5
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM	5
GENETHON	5
GSF FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT	5
INSTITUT CURIE	5
KATHOLIEKE UNIVERSITEIT LEUVEN	5
KING'S COLLEGE LONDON	5
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN	5
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS	5
RUPRECHT KARLS UNIVERSITAET HEIDELBERG	5
UNIVERSITAT AUTONOMA DE BARCELONA	5
UNIVERSITY OF AARHUS	5
UNIVERSITY OF LEEDS	5
VRIJE UNIVERSITEIT BRUSSEL	5
ACIES SAS	4
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS	4
CENTRO DE INVESTIGACIONES ENERGETICAS MEDIOAMBIENTALES Y TECNOLOGICAS	4
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS	4
DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG	4
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE	4
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V	4
GATC BIOTECH	4
IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE	4
INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE	4
ISTITUTO EUROPEO DI ONCOLOGIA	4
MEDIZINISCHE HOCHSCHULE HANNOVER	4
MEDIZINISCHE UNIVERSITAET INNSBRUCK	4
MEDIZINISCHE UNIVERSITAET WIEN	4
STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS	4
THE UNIVERSITY OF WARWICK	4
UNIVERSITAET ZUERICH	4
UNIVERSITE DE LAUSANNE	4
UNIVERSITEIT GENT	4
UNIVERSITEIT UTRECHT	4
UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND DUBLIN	4
UNIVERSITY OF TURKU	4
UPPSALA UNIVERSITET	4
ACADEMISCH ZIEKENHUIS GRONINGEN	3
ALBERT LUDWIGS UNIVERSITAET FREIBURG	3
ARTTIC	3
BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING	3
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES	3
CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY	3
COMMISSARIAT A L'ENERGIE ATOMIQUE	3
COMMISSION OF THE EUROPEAN COMMUNITIES DIRECTORATE GENERAL JOINT RESEARCH CENTRE JRC	3
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER	3
EBERHARDKARLSUNIVERSITAET TUEBINGEN	3
EUROPAEISCHES INSTITUT FUER FORSCHUNG UND ENTWICKLUNG VON TRANSPLANTATIONSSTRATEGIEN	3
FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY VZW	3
FOUNDATION FOR GENOMICS & POPULATION HEALTH	3
GEORG SPEYER HAUS CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT	3
HELMHOLTZZENTRUM FUER INFEKTIONSFORSCHUNG	3
INSERM TRANSFERT	3
INSTITUT GUSTAVE ROUSSY	3
INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL	3
ISTITUTO SUPERIORE DI SANITA	3
LUDWIG INSTITUT FUER KREBSFORSCHUNG	3
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN	3
MOLECULAR MEDICINE	3
NATIONAL UNIVERSITY OF IRELAND GALWAY	3
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON	3
QUEENSLAND INSTITUTE OF MEDICAL RESEARCH	3
THE BABRAHAM INSTITUTE	3
THE HEBREW UNIVERSITY OF JERUSALEM	3
THE UNIVERSITY OF LIVERPOOL	3
UNIVERSIDAD DE NAVARRA	3
UNIVERSITA DEGLI STUDI DI MILANO BICOCCA	3
UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II	3
UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA	3
UNIVERSITA VITA SALUTE SAN RAFFAELE	3
UNIVERSITAET BERN	3
UNIVERSITAETSKLINIKUM FREIBURG	3
UNIVERSITE LIBRE DE BRUXELLES	3
UNIVERSITEIT MAASTRICHT	3
UNIVERSITEIT VAN AMSTERDAM	3

Constancy:

Total number of partners:1361

Partner loyalty:
Frequent Partner: (> 2 projects): 537
Rare Partner: 824

Frequent / Rare Partner Ratio: 0.65

Diversity:

Subjects:

Subject:	No:
MEDICINE	51
HEALTH	51
LIFE SCIENCES	50
MEDICINE, HEALTH	49
BIOTECHNOLOGY	35
SCIENTIFIC RESEARCH	32
SOCIAL ASPECTS	21
TRAINING	20
EDUCATION	20
COOPERATION	11
COORDINATION	11
COORDINATION, COOPERATION	11
MEDICAL BIOTECHNOLOGY	10
MEDIA	8
INFORMATION, MEDIA	8
INFORMATION	8
EVALUATION	8
REGIONAL DEVELOPMENT	6
FOOD	4
EMPLOYMENT ISSUES	3
POLICIES	3
BUSINESS ASPECTS	2
INNOVATION	2
INFORMATION PROCESSING	2
HEALTHCARE DELIVERY/SERVICES	2
TECHNOLOGY TRANSFER	2
INFORMATION SYSTEMS	2
INFORMATION PROCESSING, INFORMATION SYSTEMS	1
SECURITY	1
LEGISLATION	1
NANOTECHNOLOGY AND NANOSCIENCES	1
INNOVATION, TECHNOLOGY TRANSFER	1
MATHEMATICS	1
ECONOMIC ASPECTS	1
AGRICULTURAL BIOTECHNOLOGY	1
SAFETY	1
REGULATIONS	1
NETWORK TECHNOLOGIES	1
FORECASTING	1

Diversity index:0.27

Categories:

Category:	No:
BIOLOGICAL SCIENCES	78
RTD HORIZONTAL TOPICS	36
SOCIAL AND ECONOMIC CONCERNS	23
AGRICULTURE AND MARINE RESOURC	5
INDUSTRY AND TECHNOLOGY	4
PHYSICAL AND EXACT SCIENCES	1
PROTECTING MAN AND HIS ENVIRON	1

Project overview:

Start date	Project	acronym	role	funding	partners
2018-08-01	Image-based analysis for drug discovery and repurposing	REMATCH	coordinator	149.500	1
2018-01-01	Systems Medicine of Metabolic-Signaling Networks: A New Concept for Breast Cancer Patient Stratification	MESI-STRAT	participant	5.949.964	14
2017-10-01	Detecting, understanding and exploiting intracellular redox signaling relays	Redox Relays	participant	2.006.250	1
2017-09-01	Centre of Excellence in Digital Health and Personalised Medicine	Clinnova	participant	399.800	5
2017-07-01	Endogenous barcoding for in vivo fate mapping of lineage development in the blood and immune system	BARCODED-CELLTRACING	participant	2.500.000	1
2017-03-01	Regulation of Cellular Growth and Metabolism by C18:0	C18Signaling	participant	2.000.000	1
2016-11-07	Deciphering the machinery involved in stability of the transcription factor HOXA9.	HOXA9 degradome	coordinator	239.861	1
2016-06-01	Overcoming the epigenetic and therapeutic barrier of EVI1-overexpressing cancers	EVI1inCancer	coordinator	1.499.094	1
2016-01-01	Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities.	HEP-CAR	participant	5.698.310	10
2016-01-01	RNA EDITING IN HEALTH AND DISEASE	RNAEDIT	participant	2.270.000	3
2015-09-01	Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes	B-CAST	participant	5.983.356	13
2015-07-01	Computational Biophotonics for Endoscopic Cancer Diagnosis and Therapy	COMBIOSCOPY	participant	1.499.699	3
2015-07-01	Regulating the immune regulators: targeting adaptive immune control	REGiREG	participant	1.955.000	1
2015-06-01	Dissection of tumor heterogeneity in vivo	CancerHetero	coordinator	2.000.000	1
2015-01-01	The RANK-Axis in Breast Cancer: A comprehensive prospective evaluation of promising novel biomarkers	RANKL_OPG	coordinator	168.794	1
2015-01-01	Development of Selective Carbohydrate Immunomodulators Targeting C-type Lectin Receptors on Antigen Presenting Cells	IMMUNOSHAPE	participant	3.811.581	15
2015-01-01	Epigenetic regulation of endocrine therapy resistance in breast cancer: A systems medicine approach to predict treatment outcome	EpiPredict	participant	2.797.697	8
2014-09-01	Identifying and characterising transmembrane transporters of tryptophan and kynurenine in normal and cancerous brain tissue	KP TRANSPORT	coordinator	161.969	1
2014-04-01	Mechanisms of Mismatch repair inactivation and identification of genes suppressing mutations	IMMR	coordinator	100.000	1
2013-11-01	Immunostimulatory Agonist antibodies for Cancer Therapy	IACT	coordinator	5.995.747	10
2013-10-01	Validating predictive models of radiotherapy toxicity to improve quality-of-life and reduce side-effects in cancer survivors	REQUITE	participant	5.997.408	15
2013-09-01	T-cell based immunotherapy in pancreatic cancer - basic concepts and pre-clinical development	TIPC_TIL_IP	coordinator	100.000	1
2013-06-01	Analysis of Tenascin C function in breast cancer metastasis to bone	BONEMETTNC	coordinator	100.000	1
2013-05-01	Quantitative T cell Immunology	QUANTI	participant	4.012.570	12
2013-05-01	Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer	SUPERSIST	participant	5.999.997	5
2013-05-01	Deciphering the regulatory T cell repertoire: towards biomarkers and biotherapies for autoimmune diseases	TRIPOD	participant	2.500.000	2
2013-02-01	PIVOTAL ASSESSMENT OF THE EFFECTS OF BIOACTIVES ON HEALTH AND WELLBEING. FROM HUMAN GENOMA TO FOOD INDUSTRY - PATHWAY	PATHWAY-27	participant	5.999.231	25
2013-01-01	Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action	EUROFANCOLEN	participant	5.380.170	11
2013-01-01	Early warning signals of ageing in human stem cells and age-related disorders	SYSTEMAGE	participant	5.989.925	9
2012-12-01	Systems medicine of chronic inflammatory bowel disease	SYSMEDIBD	participant	11.999.998	12
2012-12-01	Gene Therapy for X-linked Chronic Granulomatous Disease (CGD)	NET4CGD	participant	5.999.607	11
2012-10-01	Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes	DIABIL-2	participant	5.900.000	6
2012-08-01	Infrastructure for Systems Biology - Europe	ISBE	participant	4.745.718	23
2012-08-01	Global Mapping of Synthetic Genetic Interactions in Drosophila	SYNGENE	participant	2.500.000	1
2012-06-01	Generating self-antigen diversity in the thymus: from gene expression patterns in single cells to the system level, an integrative approach	Self-tolerance	participant	2.014.560	1
2012-05-01	Unlocking the potential of ultra-high-field MRI through manipulation of radiofrequency excitation fields in human tissue	MRexcite	participant	2.099.996	2
2012-03-07	Regulation of Argonaute-2 and miRNA-dependent mRNA decay in response to oxidative stress and DNA damage	mirnaAGOddr	coordinator	167.390	1
2012-02-01	Defining the Impact of Chromosome Instability in Tumor Initiation, Maintenance and Relapse	MADCIN	participant	1.500.000	2
2012-01-01	EPIC-CVD: Individualised CVD risk assessment: tailoring targeted and cost-effective approaches to Europe's diverse populations	EPIC-CVD	participant	5.987.266	30
2012-01-01	The DNA damage response pathway in MYCN amplified neuroblastoma	DDR-MYCN-NB	coordinator	169.363	1
2012-01-01	Target binders	TARGETBINDER	participant	3.988.730	10
2011-12-01	Development of a therapeutic HPV vaccine via target epitope identification by mass spectrometry	THERAVAC	coordinator	100.000	1
2011-10-01	Recruitment and activation of brown adipocytes as preventive and curative therapy for type 2 diabetes	DIABAT	coordinator	5.999.998	21
2011-09-01	Role of human papillomavirus infection and other co-factors in the aetiology of head and neck cancer in India and Europe	HPV-AHEAD	participant	2.999.946	11
2011-04-01	EU and North African Migrants: Health and Health Systems	EUNAM	coordinator	1.998.430	8
2011-02-01	A SOCIAL COLLABORATIVE WORKING SPACE SEMANTICALLY INTERLINKING BIOMEDICAL RESEARCHERS, KNOWLEDGE AND DATA FOR THE DESIGN AND EXECUTION OF IN-SILICO MODELS AND EXPERIMENTS IN CANCER CHEMOPREVENTION	GRANATUM	participant	2.995.000	7
2011-01-01	A European Platform for Translational Cancer Research	EUROCANPLATFORM	participant	11.998.454	28
2011-01-01	Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria	AIPGENE	participant	3.308.154	7
2011-01-01	Detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems	DETECTIVE	participant	4.337.425	15
2010-11-01	ASSET: Analysing and Striking the Sensitivities of Embryonal Tumours	ASSET	participant	11.999.156	19

overview shows latest 50 from 123 projects (2000-01-01 - 2019-12-31)
A full list of projects can be found here:

Alias institution names:

DEUTSCHES KREBSFORSCHUNGSZENTRUM

Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum